雷特格韦
病毒学
整合酶抑制剂
病毒载量
整合酶
外周血单个核细胞
低谷(经济学)
槽水位
杜鲁特格拉维尔
人类免疫缺陷病毒(HIV)
医学
生物
抗逆转录病毒疗法
内科学
遗传学
体外
移植
经济
宏观经济学
他克莫司
作者
Emanuele Nicastri,Chiara Tommasi,Isabella Abbate,Stefano Bonora,Massimo Tempestilli,Rita Bellagamba,Magdalena Viscione,Gabriella Rozera,Anna Loredana Gallo,Jelena Ivanović,Alessandra Amendola,Leopoldo Paolo Pucillo,Giovanni Di Perri,Maria Rosaria Capobianchi,Pasquale Narciso
摘要
BACKGROUND: Raltegravir is the first approved antiretroviral able to prevent HIV genome integration into the host chromosomes. The aim of the study is to test if raltegravir plasma concentrations can be associated with proviral DNA decline during raltegravir-based salvage therapy. METHODS: A total of 33 multidrug-resistant HIV-infected patients were enrolled in a longitudinal open-label pilot study and completed a 24-week follow-up. The CD4(+) T-cell count, plasma viral load, proviral HIV DNA and two-long-terminal repeat (2-LTR) circular forms were assessed at baseline, day 14, 30, 60, 90 and 180. The raltegravir trough concentration (C (trough)) was measured by HPLC-ultraviolet and patients were divided into two groups according to the median raltegravir C (trough). RESULTS: The mean±SD values of baseline HIV RNA, CD4(+) T-cell count and HIV DNA were 4.4±0.82 log copies/ml, 256±177 cells/mm(3) , and 2,668±4,721 copies/10(6) peripheral blood mononuclear cells, respectively. Despite a transient increase of total DNA at week 2, a marked proviral DNA decay (P=0.01) with an increase of the 2-LTR unintegrated/total DNA ratio (P=0.06) over time was observed. At univariate analysis, no correlation between raltegravir C(trough) and classical virological parameters was observed. Nevertheless, the decay of proviral HIV DNA was more pronounced in patients displaying C(trough)<158 ng/ml with respect to those with C(trough)>158 ng/ml (P=0.046). CONCLUSIONS: Successful raltegravir-based therapy produces a significant decline in proviral DNA and is associated with an increase of the unintegrated/total DNA ratio. Further studies are necessary to define the possible role of pharmacokinetic raltegravir monitoring and the biological meaning of unintegrated proviral DNA.
科研通智能强力驱动
Strongly Powered by AbleSci AI